Skip to main content

Table 1 Patient demographics and clinical characteristics a

From: Synovial explant inflammatory mediator production corresponds to rheumatoid arthritis imaging hallmarks: a cross-sectional study

Variables Observations (N= 25)
Females, n (%) 19 (76%)
Mean age ± SD, yr (IQR) 56.2 ± 14.9 (26 to 77)
Disease duration, yr 12.3 [4.0 to 14.1] (0.9; 42.7)
RF-positive, n (%) 21 (84%)
Anti-CCP-positive, n (%) 22 (88%)
Mean DAS-28-CRP score (0 to 10) 4.8 ± 1.3 [2.2 to 6.8]
CRP, mg/L 20.9 [4 to 30] (1; 117)
VAS global (scale 0 to 100) 62.5 [41 to 83]
Tender joint count, 28 joints 7.1 [4 to 9] (0; 25)
Swollen joint count, 28 joints 7.8 [4 to 9] (1; 21)
DMARD monotherapy  
 MTX, n (%) 2 (8%)
 SZS, n (%) 3 (12%)
 LFU, n (%) 2 (8%)
DMARD combination treatment  
 MTX + SZS, n (%) 4 (16%)
 MTX + SZS + HCQ, n (%) 3 (12%)
 Biologic DMARDs (%) 8 (32%)
 Prednisolone monotherapy, 5 mg/day 2 (8%)
 No DMARDs (%) 1 (4%)
  1. aCCP, Cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; HCQ, Hydroxychloroquine; LFU, Leflunomide; MCP, Metacarpophalangeal joint; MTX, Methotrexate; PIP, Proximal interphalangeal joint; RF, Rheumatoid factor; SD, Standard deviation; SZS, Sulphasalazine; VAS, Visual Analogue Scale. Values are median [Q1 to Q3], (min; max) or mean ± SD unless otherwise stated.